Impact News +++ Sunbelt Rentals Appoints Ekta Singh-Bushell to Board of Directors (Business Wire) +++ TTEC Aktie +3,55%

OCUGEN Aktie

>OCUGEN Aktienkurs

1.262 EUR -2.3% (TradegateBSX)

Ask: 1.252 EUR / 10000 Stück

Bid: 1.234 EUR / 10000 Stück

Tagesumsatz: 174716 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OCUGEN Aktie über LYNX handeln

Intraday

1 Jahr

>OCUGEN Performance

1 Woche: -3,1%

1 Monat: +20,2%

3 Monate: -16,5%

6 Monate: -24,2%

1 Jahr: +30,1%

laufendes Jahr: +0,8%

>OCUGEN Aktie

Profil:

Ocugen Inc. is a biopharmaceutical company headquartered in Malvern, Pennsylvania, specializing in the discovery, development, and commercialization of gene therapies, cell therapies, and vaccines. The company's primary focus centers on rare inherite..
>Volltext..

Insiderhandel:

>OCUGEN Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>OCUGEN Peer Group

Gesundheit, Augenmedizin/ Sehhilfen, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten, Allergiebehandlung, Infektionskrankheiten/ Impfstoffentwicklung/ Antibiotika
>Alle Branchen..

>OCUGEN Chart & Kurs - NASDAQ

>OCUGEN News

13.07.26 - 13:27	Ocugen signs OCU400 licensing term sheet (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

13.07.26 - 13:06

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa (GlobeNewswire EN)

MALVERN, Pa., July 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a license agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region....

10.07.26 - 16:54	Ocugen treibt Gentherapie-Pipeline für Augenerkrankungen voran (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

01.07.26 - 13:03	Ocugen to Participate in Upcoming July Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in July 2026....

18.06.26 - 03:01	Insiderhandel: Chief Financial Officer kauft Aktien von Ocugen im Wert von 25830 USD (Insiderkauf)
	Johnson-Greene, Treerita Essalima - Vorstand - Tag der Transaktion: 2026-06-15...

04.06.26 - 19:00	Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report? (Zacks)
	Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues....

03.06.26 - 19:45	Ocugen′s Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care (Zacks)
	OCGN is advancing gene-agnostic eye therapies across retinal diseases, with key trial data and regulatory milestones approaching in 2026 and 2027....

03.06.26 - 19:00	Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data? (Zacks)
	Ocugen faces cash burn and dilution risks, but upcoming eye gene therapy data and planned filings through 2027 could shape its next phase....

03.06.26 - 19:00	OCGN′s Catalyst Calendar for Trial Data and Filings Through 2028 (Zacks)
	Ocugen's three ocular gene therapy programs could deliver trial data, filings, and potential BLA milestones through 2028 as key readouts approach....

02.06.26 - 13:06	Ocugen to Participate in Upcoming June Investor and Industry Conferences (GlobeNewswire EN)
	MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in June 2026....

26.05.26 - 10:27	Russell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop off (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.05.26 - 10:00	Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

14.05.26 - 22:33	Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes (GlobeNewswire EN)
	Includes Full Exercise of $15.0 million Over-Allotment Option Includes Full Exercise of $15.0 million Over-Allotment Option...

13.05.26 - 13:06	Ocugen to Participate in Upcoming May Scientific and Investor Conferences (GlobeNewswire EN)
	MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific and investor conferences in May 2026....

11.05.26 - 17:07	Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.05.26 - 19:45	Ocugen (OCGN) Upgraded to Buy: Here′s Why (Zacks)
	Ocugen (OCGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....

06.05.26 - 19:45	OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress Outlook (Zacks)
	Ocugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track....

06.05.26 - 09:54	Ocugen Aktie explodiert nach unten: Wie tief geht es noch? (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.26 - 21:00	Ocugen outlines plan for 3 BLAs by 2028 as it expects cash runway into 2028 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.05.26 - 17:48	Ocugen stock dips as Q1 losses widen (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Ein Hafen ist ein reizvoller Aufenthalt für eine im Lebenskampf erschöpfte Seele. - Charles Baudelaire

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram